A Good Cancer research Bio company? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Good Cancer research Bio company?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: B. Ino who wrote ()	11/7/1996 8:51:00 AM
From: Henry Niman	of 76

LGND investors should note that the JAMA press release indicated that the editorial stated "The uncertainty regarding the risk of breast cancer in patients who use HRT is highlighted in the SOF report, but recent advances in understanding the molecular basis for tissue-specific estrogen responses may soon lead to the development of tissue-specific estrogens that could eliminate this concern, according to the editorialists." This statement is of particular importance to LGND investors. LGND's screening process directly addresses these issues and the focus of the AHP alliance on "tissue-specific estrogen analogs" should not be overlooked.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next